GSK Arm Wins Appeal In Cancer Drug Royalties Dispute
A GlaxoSmithKline unit won its appeal Friday to avoid having to pay royalties to AstraZeneca on all sales of its ovarian cancer drug under a licensing agreement....To view the full article, register now.
Already a subscriber? Click here to view full article